| Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival G Abu-Zeinah, S Krichevsky, T Cruz, G Hoberman, D Jaber, N Savage, ... Leukemia 35 (9), 2592-2601, 2021 | 82 | 2021 |
| Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3 N Mollé, S Krichevsky, P Kermani, RT Silver, E Ritchie, JM Scandura Blood, The Journal of the American Society of Hematology 135 (13), 1062-1066, 2020 | 30 | 2020 |
| Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm–Associated Pulmonary Hypertension J Kim, S Krichevsky, L Xie, MC Palumbo, S Rodriguez-Diego, B Yum, ... Journal of the American Society of Echocardiography 32 (12), 1574-1585, 2019 | 19 | 2019 |
| Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values RT Silver, S Krichevsky haematologica 104 (11), 2200, 2019 | 19 | 2019 |
| Prevalence and risk factors for pulmonary hypertension associated with chronic myeloproliferative neoplasms A Ferrari, J Scandura, A Masciulli, S Krichevsky, A Gavazzi, T Barbui European Journal of Haematology 106 (2), 250-259, 2021 | 13 | 2021 |
| Extracting and classifying diagnosis dates from clinical notes: a case study JT Fu, E Sholle, S Krichevsky, J Scandura, TR Campion Journal of Biomedical Informatics 110, 103569, 2020 | 13 | 2020 |
| Interferon in polycythemia vera (PV) yields improved myelofibrosis-free and overall survival G Abu-Zeinah, S Krichevsky, T Cruz, G Hoberman, N Savage, E Ritchie, ... Blood 136, 31-32, 2020 | 12 | 2020 |
| Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia N Kucine, S Bergmann, S Krichevsky, D Jones, M Rytting, J Jain, ... Pediatric blood & cancer 68 (3), e28888, 2021 | 9 | 2021 |
| Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera RT Silver, S Krichevsky, S Gjoni, NCP Cross Leukemia & lymphoma 58 (11), 2768-2769, 2017 | 9 | 2017 |
| Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (< 10%) or with other types of … JT Geyer, E Margolskee, SA Krichevsky, D Cattaneo, L Boiocchi, ... haematologica 105 (5), e221, 2020 | 8 | 2020 |
| Acute myeloid leukemia (AML) with somatic mutations in PTPN11 is associated with treatment resistance and poor overall survival JD Kaner, N Mencia-Trinchant, A Schaap, GJ Roboz, S Lee, P Desai, ... Blood 132, 2760, 2018 | 8 | 2018 |
| Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients E Margolskee, S Krichevsky, A Orazi, RT Silver haematologica 102 (3), e97, 2017 | 7 | 2017 |
| Lessons learned in the development of a computable phenotype for response in myeloproliferative neoplasms E Sholle, S Krichevsky, J Scandura, C Sosner, T Campion 2018 IEEE International Conference on Healthcare Informatics (ICHI), 328-331, 2018 | 6 | 2018 |
| Use of pegylated interferon in six pediatric patients with myeloproliferative neoplasms N Kucine, S Bergmann, S Krichevsky, D Jones, ME Rytting, L Resar, ... Blood 134, 4194, 2019 | 4 | 2019 |
| A novel machine learning-derived dynamic scoring system predicts risk of thrombosis in polycythemia vera (PV) patients G Abu-Zeinah, S Krichevsky, RT Silver, E Taylor III, D Tremblay, ... Blood 138, 3619, 2021 | 3 | 2021 |
| Myeloproliferative neoplasm (MPN) driver mutations are enriched during hematopoietic stem cell differentiation in patterns that correlate with clinical phenotype and treatment … G Abu-Zeinah, S Di Giandomenico, C Sosner, N Savage, S Krichevsky, ... Blood 132, 4317, 2018 | 3 | 2018 |
| Incidence of infections and second cancers in Philadelphia chromosome-negative patients with myeloproliferative neoplasms treated with ruxolitinib EK Ritchie, S Krichevsky, GJ Roboz, RT Silver, AI Schafer, J Scandura, ... Blood 130, 2910, 2017 | 2 | 2017 |
| Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera S Krichevsky, G Abu-Zeinah, K Erdos, JM Scandura Blood 142, 3186, 2023 | 1 | 2023 |
| A Deep Learning-Based Pathomics Methodology for Quantifying and Characterizing Nucleated Cells in the Bone Marrow Microenvironment S Krichevsky, MM Ouseph, Y Zhang, G Abu-Zeinah, JM Scandura, ... Blood 142, 2294, 2023 | 1 | 2023 |
| Unbiased identification of thrombosis risk factors in polycythemia vera (PV) using machine learning and rich data from automated extraction of medical records generates dynamic … G Abu-Zeinah, S Krichevsky, K Erdos, RT Silver, J Scandura Blood 140 (Supplement 1), 3961-3962, 2022 | 1 | 2022 |
Ghaith Abu-ZeinahNew York Presbyterian/ Weill Cornell Medicine在 med.cornell.edu 的电子邮件经过验证
